Abrocitinib (PF-04965842) is a potent and selective oral inhibitor of JAK1, demonstrating high selectivity over JAK2 (IC50s: 29 nM and 803 nM, respectively). It is a valuable research tool for investigating JAK1-mediated pathways in immunological and inflammatory diseases, with utility in both in vitro and in vivo preclinical studies.